PrEP has become more mainstream in the media, and the USPSTF recently recommended PrEP for all at-risk populations. Richard Chaisson, MD, shines light on these at-risk populations.
In this Q&A, Monica Gandhi, MD, MPH, discusses interventions to address the health care disparities that exist along the care continuum for certain patient populations who are at-risk for HIV...
New research indicates that many women living with HIV may prefer a monthly long-acting injectable antiretroviral therapy, once FDA-approved, instead of daily pills. Consultant360 discussed these findings...
Consultant360 spoke with Keith Horvath, PhD, about his study, which indicated that technology-assisted HIV testing interventions could serve as a key strategy in reaching national and global targets for HIV...
Kathleen Ryan, PhD, answered our questions about her study, which indicated that rapid scale-up of PrEP was possible without the consequence of reduced HIV testing among Australian gay, bisexual, and other...
Jason J. Ong, PhD, MBBS, from the London School of Hygiene and Tropical Medicine, answers our questions about his team’s research on STI prevalence and incidence among new and persistent users of...
A new study of more than 27,000 MSM has indicated that increased HIV PrEP use has unexpectedly led to decreased condom use among men not using PrEP. Consultant360 spoke with lead study author Martin Holt,...
